An Indispensable Partner

To fulfill the promise of on-target gene editing from discovery to patient

[ Company Overview ]

Physicians and regulators are concerned that changes to a patient’s genome might have unintended, life-altering consequences

It will be imperative to understand the off-target risk profile of your therapy to inform regulatory filings, support patient and clinician decision making, and to conduct post market surveillance

Invaluable gene editing off-target insights from initial research to patient therapies

Through every phase of development, our portfolio of solutions assesses and identifies both on-target specificity and off-target risks to support research and development, inform study design, enable clinical trial enrollment, and ensure access to therapy in the clinic.

Discovery features
Development features
Commercialization features

SeQure Dx comprehensively evaluates and confirms on- and off-target events using proprietary analytical tools that deliver unparalleled sensitivity and scalability.

Our diagnostics are editor-agnostic and scalable — providing both individual and population level insight.

Join the team – help us make safe gene editing a reality

Come join an energetic, focused, and dynamic team that supports career growth as well as personal well-being.

  • Reflecting on a year of achievements and learning at SeQure Dx

    As the calendar flips to 2024, we at SeQure Dx find ourselves at an exhilarating crossroads. With a year of groundbreaking achievements behind us and the horizon filled with promising opportunities, we're eager to share our journey and the future we're passionately working towards.Full Release ❯

  • Synthego and SeQure Dx Partner to Provide Comprehensive Off-Target Analysis Services for CRISPR-Based Therapeutics Developers

    Synthego, a leading provider of genome engineering solutions, and SeQure Dx, a company focused on off-target analysis for preclinical and clinical gene modification customers, have announced a strategic partnership to provide CRISPR-based therapeutics developers with comprehensive off-target editing analytical services that include best-in-class technology and turn-key end-to-end development solutions.Full Release ❯